Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198377 | 0.87 | METAP1 (0.41) | CYP1A2SIGMAR1SHBGMETAP1EPHX1 | |
| SCHEMBL28240915 | 0.77 | SHBG (0.48) | CYP1A2SIGMAR1SHBGMETAP1EPHX1 | |
| SCHEMBL3955840 | 0.75 | CYP1A2 (0.41) | CYP1A2SIGMAR1METAP1EPHX1HPGD | |
| SCHEMBL8943489 | 0.73 | SHBG (0.45) | CYP1A2SIGMAR1SHBGEPHX1 | |
| SCHEMBL196915 | 0.73 | EPHX1 (0.37) | CYP1A2SHBGEPHX1 | |
| SCHEMBL27580674 | 0.72 | SHBG (0.43) | CYP1A2SIGMAR1SHBGEPHX1 | |
| SCHEMBL3957635 | 0.72 | CYP1A2 (0.38) | CYP1A2SIGMAR1METAP1EPHX1 | |
| SCHEMBL8082088 | 0.72 | CYP1A2 (0.42) | CYP1A2SIGMAR1SHBGMETAP1EPHX1 | |
| SCHEMBL7434472 | 0.72 | CYP1A2 (0.42) | CYP1A2SIGMAR1SHBGMETAP1EPHX1 | |
| SCHEMBL16418310 | 0.72 | CYP1A2 (0.52) | CYP1A2SIGMAR1SHBGMETAP1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293905-B2 | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8088883-B2 | Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| CN-101772508-A | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL CO | 2010-07-07 | — | — | CN | disclosed |
| EP-2192124-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| EP-2172470-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20090048413-A1 | Method for Production of Conjugated Polymer | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-02-19 | — | — | US | disclosed |
| EP-1997844-A1 | METHOD FOR PRODUCTION OF CONJUGATED POLYMER | Sumitomo Chemical Company, Limited (JP) | 2008-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | CYP1A2 191/4885SIGMAR1 3855/4885SHBG 3457/4885 |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | CYP1A2 228/4885SIGMAR1 2897/4885SHBG 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.